Pharmaceuticals, Biotechnology and Life Sciences
Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, has announced today that the Carragelose-based nasal spray has been out-licensed for the South Korean market.
Recipharm, a global contract development and manufacturing organisation (CDMO), has announces the closing of its acquisitions of advanced therapy CDMO Arranta Bio and virotherapy CDMO Vibalogics.
Global pharmaceutical contract packaging organisation (CPO), Tjoapack has completed its expansion plans following a €10m+ plus investment at its Etten-Leur facility in the Netherlands.
Moderna, Inc. (NASDAQ:MRNA), has announced the first participants have been dosed in the Phase 1/2 study of the company’s seasonal influenza vaccine candidates, mRNA-1020 and mRNA-1030.
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), has announced positive results from preclinical studies evaluating an anti-HER3 antibody, conjugated with an Actinium-225 (Ac-225) radioisotope payload, for targeting HER3-positive non-small cell lung cancer (NSCLC) cells.
Adrenomed AG, the vascular integrity company, has announced that its proprietary sepsis drug candidate Adrecizumab (HAM8101) received a funding commitment of € 7.4 million from the German Federal Ministry of Education and Research (BMBF) as part of the German funding initiatives for the clinical development of COVID-19 drugs and their manufacturing capabilities.
SciRhom GmbH has nominated the anti-iRhom2 antibody it will advance into clinical development. For this antibody, the company has closed an agreement with a top-tier biopharmaceutical manufacturer for the CMC development.
Affimed N.V. (Nasdaq: AFMD) has provided a data update from the ongoing study of the company’s lead innate cell engager (ICE) AFM13 precomplexed with cord blood-derived natural killer (cbNK) cells.
Genmab A/S (Nasdaq: GMAB) announced today an award in the binding arbitration of two matters arising under its license agreement with Janssen Biotech, Inc. (Janssen) relating to daratumumab.
Glatt Ingenieurtechnik GmbH opened a new branch in Cologne. The new unit will showcase the company’s pharmaceutical, biotechnology and active ingredient plant expertise and represents Glatt’s first location in North Rhine-Westphalia.